Articles related to ACUTE MYELOID LEUKEMIA (AML)

In this series from Blood that tackles four cases studies, the outcomes of AML pediatric patients compared to children with ALL is explored, focusing on the emerging new treatments venetoclax (Venclexta; AbbVie/Genentech), CD33- and CD123-directed CAR T-cell therapy, CD123-directed antibody therapy, and menin inhibitors.

About 75% to 80% of children with pediatric AML have clonal, acquired, somatic cytogenetic abnormalities (CAs) detected. Hematology Advisor briefs the information originally appearing in Genes, which reviews the current knowledge on evaluating pediatric patients based on cytogenetics and molecular subtypes to help match patients to risk-adapted therapies.

Key Points: In two study cohorts, less-intensive therapies increased mortality in each of three risk groups defined by age, comorbidities, and cytogenetics. The differences became nonsignificant after accounting for physician perception of cure, emphasizing the need for a randomized trial.Design: Multicenter retrospective cohort (1,292), 6 institutions, 2008-2012; prospective cohort (695), 13 institutions, 2013 – 2017Connected Content: Fitness for Intensive Chemotherapy: A Continuing Conundrum

In this Clinical Advances in Hematology & Oncology Q&A with Dr. Tapan M. Kadia, an associate professor at the MD Anderson Cancer Center, the current treatments for acute myeloid leukemia (AML) are discussed, with a specific focus on the targeted FLT3 approach, the role of the gene in AML, the differences among the approved FLT3 inhibitors, and why newer FLT3 inhibitors are needed.

In this Q&A, Dr. Gautam Borthakur from the University of Texas MD Anderson Cancer Center talks with Clinical Advances in Hematology & Oncology about the goals, treatment options (including tailored treatment), differences in de novo vs. therapy-related, and other suggestions in patients with core-binding factor acute myeloid leukemia (AML).